Current issues in the management of Tuberculosis in Europe

Panminerva Medica

Volumn 55, Issue 2, 2013, Pages 145-155

  Zellweger, J P ^a  

^a Swiss Lung Association   (Switzerland)

Author keywords

Public health; Transient and migrants; Tuberculosis

Indexed keywords

BCG VACCINE; TUBERCULOSTATIC AGENT;

ARTICLE; DISEASE ERADICATION; DISEASE TRANSMISSION; EUROPE; HUMAN; MASS SCREENING; METHODOLOGY; MIGRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BCG VACCINE; DISEASE ERADICATION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EMIGRANTS AND IMMIGRANTS; EMIGRATION AND IMMIGRATION; EUROPE; HUMANS; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TRANSIENTS AND MIGRANTS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84880113056     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. Stockholm: European Centre for Disease Prevention and Control; 2012.
2. 3.
3. Zumla A. The white plague returns to London-with a vengeance. Lancet 2011;377:10-1.
4. O'Grady J, Maeurer M, Atun R, Abubakar I, Mwaba P, Bates M et al. Tuberculosis in prisons: anatomy of global neglect. Eur Respir J 2011;38:752-4.
5. World health Organization. Global Tuberculosis report 2012. Geneva: WHO; 2012.
6. Khan M, Dar O, Sismanidis C, Shah K, Godfreyfaussett P. Improvement of tuberculosis case detection and reduction of discrepancies between men and women by simple sputum-submission instructions: a pragmatic randomised controlled trial. Lancet 2007;369:1955-60.
7. Alisjahbana B, van Crevel R, Danusantoso H, Gartinah T, Soemantri ES, Nelwan RH et al. Better patient instruction for sputum sampling can improve microscopic tuberculosis diagnosis. Int J Tuberc Lung Dis 2005;9:814-7.
8. Moore HA, Apolles P, de Villiers PJ, Zar HJ. Sputum induction for microbiological diagnosis of childhood pulmonary tuberculosis in a community setting. Int J Tuberc Lung Dis 2011;15:1185-90, i.
9. Minion J, Sohn H, Pai M. Light-emitting diode technologies for TB diagnosis: what is on the market? Expert Rev Med Devices 2009;6:341-5.
10. Albert H, Manabe Y, Lukyamuzi G, Ademun P, Mukkada S, Nyesiga B et al. Performance of three LED-based fluorescence microscopy systems for detection of tuberculosis in Uganda. PLoS ONE 2010;5:el5206.
11. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377:1495-505.
12. Drobniewski F, Nikolayevskyy V, Balabanova Y, Bang D, Papaventsis D. Diagnosis of tuberculosis and drug resistance: what can new tools bring us? Int J Tuberc Lung Dis 2012;16:860-70.
13. Kherad O, Herrmann FR, Zellweger JP, Rochat T, Janssens JP. Clinical presentation, demographics and outcome of tuberculosis (TB) in a low incidence area: a 4-year study in Geneva, Switzerland. BMC Infect Dis 2009;9:217.
14. Wallace RM, Kammerer JS, Iademarco MF, Althomsons SP, Winston CA, Navin TR. Increasing proportions of advanced pulmonary tuberculosis reported in the United States: are delays in diagnosis on the rise? AJRCCM 2009;180:1016-22.
15. Verver S, Bwire R, Borgdorff MW. Screening for pulmonary tuberculosis among immigrants: estimated effect on severity of disease and duration of infectiousness. Int J Tuberc Lung Dis 2001;5:419-25.
16. Oni T, Burke R, Tsekela R, Bangani N, Seldon R, Gideon HP et al. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax 2011;66:669-73.
17. Storia DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 2008;8:15.
18. Rabin AS, Kuchukhidze G, Sanikidze E, Kempker RR, Blumberg HM. Prescribed and self-medication use increase delays in diagnosis of tuberculosis in the country of Georgia. Int J Tuberc Lung Dis 2013;17:214-20.
19. Rieder HL, Zellweger JP, Raviglione MC, Keizer ST, Migliori GB. Tuberculosis control in Europe and international migration. Eur Respir J 1994;7:1545-53.
20. Sarivalasis A, Zellweger J, Faouzi M, Daher O, Deslarzes C, Bodenmann P. Factors associated with latent tuberculosis among asylum seekers in Switzerland: a cross-sectional study in Vaud County. BMC Infectious Diseases 2012;12:285.
21. Klinkenberg E, Manissero D, Semenza JC, Verver S. Migrant tuberculosis screening in the EU/EEA: yield, coverage and limitations. Eur Respir J 2009;34:1180-9.
22. Schneeberger Geisler S, Helbling P, Zellweger JP, Altpeter ES. Screening for tuberculosis in asylum seekers: comparison of chest radiography with an interview-based system. Int J Tuberc Lung Dis 2010;14:1388-94.
23. Arshad S, Bavan L, Gajari K, Paget SNJ, Baussano I. Active screening at entry for tuberculosis among new immigrants: a systematic review and meta-analysis. Eur Respir J 2009;35:1336-45.
24. El Hamad I, Casalini C, Matteelli A, Casari S, Bugiani M, Caputo M et al. Screening for tuberculosis and latent tuberculosis infection among undocumented immigrants at an unspecialised health service unit. Int J Tuberc Lung Dis 2001;5:712-6.
25. Bodenmann P, Vaucher P, Wolff H, Favrat B, de Tribolet F, Masserey E et al. Screening for latent tuberculosis infection among undocumented immigrants in Swiss healthcare centres; a descriptive exploratory study. BMC Infectious Diseases 2009;9:34.
26. Ricks PM, Cain KP, Oeltmann JE, Kammerer JS, Moonan PK. Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U. S., 2005-2009. PLoS ONE 2011;6:e27405.
27. Pareek M, Baussano I, Abubakar I, Dye C, Lalvani A. Evaluation of immigrant tuberculosis screening in industrialized countries. Emerging Infectious Diseases 2012;18:1422-9.
28. Vos AM, Meima A, Verver S, Looman CW, Bos V, Borgdorff MW et al. High incidence of pulmonary tuberculosis persists a decade after immigration, The Netherlands. Emerg Infect Dis 2004;10:736-9.
29. Flynn M, Brown L, Tesfai A, Lauer T. Post-migration screening for active tuberculosis in Victoria, Australia. Int J Tuberc Lung Dis 2012;16:50-4.
30. Erkens C, Slump E, Kamphorst M, Keizer S, van Gerven PJ, Bwire R et al. Coverage and yield of entry and follow-up screening for tuberculosis among new immigrants. Eur Respir J 2008;32:153-61.
31. Breuss E, Helbling P, Altpeter E, Zellweger JP. Screening and treatment for latent tuberculosis infection among asylum seekers entering Switzerland. Swiss Med Wkly 2002;132:197-200.
32. Linas BP, Wong AY, Freedberg KA, Horsburgh Jr CR. Priorities for screening and treatment of latent tuberculosis nfection in the United States. Am J Respir Crit Care Med 2011;184:590-601.
33. Orlando G, Merli S, Cordier L, Mazza F, Casazza G, Villa AM et al. Interferon-y releasing assay versus tuberculin skin testing for latent tuberculosis infection in targeted screening programs for high risk immigrants. Infection 2010;38:195-204.
34. National Institute for Health and Clinical Excellence. Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. In: National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE, ed. London: The Royal College of Physicians; 2011.
35. Cain KP, MacKenzie WR. Editorial commentary: Overcoming the limits of tuberculosis prevention among foreign-bom individuals: next steps toward eliminating tuberculosis. Clinlnfect Dis 2008;46:107-9.
36. Mulder C, van Deutekom H, Huisman EM, Toumanian S, Koster BF, Meijer-Veldman W et al. Role of the QuantiFERON (R)-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection. European Respiratory Journal 2012;40:1443-9.
37. Dara M, de Colombani P, Petrova-Benedict R, Centis R, Zellweger JP, Sandgren A et al. Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. Eur Respir J 2012;40:1081-90.
38. Kamper-Jorgensen Z, Andersen AB, Kok-Jensen A, Kamper-Jorgensen M, Bygbjerg IC, Andersen PH et al. Migrant tuberculosis: the extent of transmission in a low burden country. BMC Infectious Diseases 2012;12:60.
39. Langlois-Kiassen D, Wooldrage KM, Manfreda J, Sutherland K, Ellis E, Phypers M et al. Piecing the puzzle together: foreignbom tuberculosis in an immigrant-receiving country. Eur Respir J 2011;38:895-902.
40. Bamiol J, Niemann S, Louis VR, Brodhun B, Dreweck C, Richter E et al. Transmission dynamics of pulmonary tuberculosis between autochthonous and immigrant subpopulations. BMC Infect Dis 2009;9:197.
41. Sails AD, Barrett A, Sarginson S, Magee JG, Maynard P, Hafeez I et al. Molecular epidemiology of Mycobacterium tuberculosis in East Lancashire 2001-2009. Thorax 2011;66:709-13.
42. Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis 2012;16:724-32.
43. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3(10 Suppl 2):S231-S79.
44. van der Werf MJ, Langendam MW, Huitric E, Manissero D. Multidrug resistance after inappropriate tuberculosis treatment: a metaanalysis. Eur Respir J 2012;39:1511-9.
45. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011;204:1951-9.
46. Van Tongeren L, Nolan S, Cook VJ, Fitzgerald JM, Johnston JC. Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis 2013;17:221-4.
47. Cox HS, Niemann S, Ismailov G, Doshetov D, Orozco JD, Blok L et al. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clin Infect Dis 2007;44:1421-7.
48. Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 2008;12:869-77.
49. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010;16:264-71.
50. Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G et al. European union standards for tuberculosis care. Eur Respir J 2012;39:807-19.
51. Steingart KR, Jotblad S, Robsky K, Deck D, Hopewell PC, Huang D et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2011;15:305-16.
52. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998;113:1178-83.
53. Chang KC, Leung CC, Grosset J, Yew WW. Treatment of tuberculosis and optimal dosing schedules. Thorax 2011;66:997-1007.
54. Maciel EL, Brioschi AP, Peres RL, Guidoni LM, Ribeiro FK, Hadad DJ et al. Smoking and 2-month culture conversion during antituberculosis treatment. Int J Tuberc Lung Dis 2013;17:225-8.
55. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneve: WHO; 2011.
56. Gier MT, Podewils LJ, Munez N, Galipot M, Quelapio MI, Tupasi TE. Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012;16:955-60.
57. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-92.
58. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008;12:139-45.
59. Torun T, Gungor G, Ozmen I, Bolukbasi Y, Maden E, Bicakci B et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:1373-7.
60. Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, Leimane V. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010;14:275-81.
61. Dartois V, Barry CE. Clinical pharmacology and lesion penetrating properties of second-and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensivelydrug resistant (XDR) tuberculosis. Curr Clin Pharmacol 2010;5:96-114.
62. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Medicine 2012;9:el001300.
63. Kempker RR, Vashakidze S, Solomonia N, Dzidzikashvili N, Blumberg HM. Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis 2012;12:157-66.
64. Gegia M, Kalandadze I, Kempker RR, Magee MJ, Blumberg HM. Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis 2012;16:e391-396.
65. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011;15:949-54.
66. Gier MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60.
67. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: longterm outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56:3271-6.
68. Loddenkemper R, Sotgiu G, Mitnick CD. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Eur Respir J 2012;40:9-11.
69. Migliori GB, Sotgiu G, D'Ambrosio L, Centis R, Lange C, Bothamley G et al. TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J 2012;39:619-25.
70. World Health Organization. Roadmap to prevent and combat drugresistant tuberculosis. Copenhagen: WHO regional office for Europe; 2011.
71. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 2008;8:359-68.
72. Moran-Mendoza O, Marion SA, Elwood K, Patrick D, Fitz Gerald JM. Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis 2010;14:1112-9.
73. Machingaidze S, Verver S, Mulenga H, Abrahams DA, Hatherill M, Hanekom W et al. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. AJRCCM 2012;186:1051-6.
74. Mandalakas AM, Hesseling AC, Gie RP, Schaaf HS, Marais BJ, Sinanovic E. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax 2013;68:247-55.
75. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010;1:CD000171.
76. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J 2013;41:140-56.
77. Borgen K, Koster B, Meijer H, Kuyvenhoven V, van der SM, Cobelens F. Evaluation of a large-scale tuberculosis contact investigation in the Netherlands. Eur Respir J 2008;32:419-25.
78. World Health Organization. Recommendations for investigating contacts of persons with infectious tuberculosis in low-and middleincome countries. Geneva: WHO; 2013.
79. Erkens CG, Kamphorst M, Abubakar I, Bothamley GH, Chemtob D, Haas W et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010;36:925-49.
80. Lange C, Rieder HL. Intention to test is intention to treat. Am J Respir Crit Care Med 2011;183:3-4.
81. Leung CC, Rieder HL, Lange C, Yew WW. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 2011;37:690-711.
82. Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010;137:401-9.
83. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis 2008;12:1352-64.
84. Hirsch-Moverman Y, Daftary A, Franks J, Colson PW. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008;12:1235-54.
85. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-66.
86. Denholm JT, Leslie DE, Jenkin GA, Darby J, Johnson PD, Graham SM et al. Long-term follow-up of contacts exposed to multidrugresistant tuberculosis in Victoria, Australia, 1995-2010. Int J Tuberc Lung Dis 2012;16:1320-5.
87. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrugresistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002;109:765-71.
88. European Centre for Disease Prevention and Control (ECDC). Management of contacts of MDR TB and XDR TB patients. Stockholm: ECDC; 2012.
89. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Medicine 2011;8:el001012.
90. Brennan MJ, Stone MR, Evans T. A rational vaccine pipeline for tuberculosis. Int J Tuberc Lung Dis 2012;16:1566-73.
91. Glaziou P, Floyd K, Korenromp EL, Sismanidis C, Bierrenbach AL, Williams BG et al. Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bulletin of the World Health Organization 2011', 89:573-82.
92. World Health Organization. Treatment of tuberculosis. Guidelines. 4th ed. Geneva: World Health Organization; 2009.
93. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Current Opinion in HIV and AIDS 2009;4:325-33.
94. Langendam MW, van der Werf MJ, Huitric E, Manissero D. Prevalence of inappropriate tuberculosis treatment regimens: a systematic review. Eur Respir J 2012;39:1012-20.
95. Zumla A, Blasi F, Raviglione M. Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance. Eur Respir J 2012;39:802-4.
96. Zumla A, Yew WW. New tools for achieving tuberculosis control: progress and reflexion. Int J Tuberc Lung Dis 2011;15:285-6.